Benzinga | Nov 12, 2020 04:08PM EST

C4 Therapeutics Q3 EPS $(17.55) Down From $(8.93) YoY, Sales $8.45M Up From $5.36M YoY

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(17.55) per share. This is a 96.53 percent decrease over losses of $(8.93) per share from the same period last year. The company reported $8.45 million in sales this quarter. This is a 57.48 percent increase over sales of $5.36 million the same period last year.